GET DAILY SIGNALSStevanato Group (STVN) Q3 2026 Earnings Preview: Watching High-Value Solutions Momentum
Key Takeaways
- Stevanato Group is scheduled to report results for the third quarter of fiscal 2026 (the three months ended September 30, 2026), with results widely expected around the first half of November 2026.
- Investors are watching whether the company sustains its high-value solutions momentum, after those products grew 16% in the second quarter and reached 45% of total revenue.
- In the second quarter, revenue rose 8% to €302 million and adjusted EBITDA climbed 21% to €78.7 million.
- Full-year 2026 guidance calls for revenue of €1.26 billion to €1.28 billion and adjusted diluted EPS of €0.60 to €0.62.
- Biologics demand, GLP-1 therapies, and the Alina pen injector platform are expected to be central topics on the earnings call.
- For additional context on STVN's Major News, Today's Price Move, Price Targets, and Forecasts, explore these dedicated pages.
- To discover automated market strategies, explore Trending AI Robots.
Why This Report Matters
Stevanato Group serves as a key supplier of drug containment, delivery, and diagnostic solutions to the pharmaceutical and biotechnology sectors. Its quarterly updates offer insight into demand trends for injectable biologics, where the company provides premium syringes, cartridges, and related devices. The upcoming release comes at a time when investors are assessing whether the ongoing shift toward higher-margin, high-value solutions can sustain both revenue growth and margin improvement. Recent quarters reflected steady progress at the new facilities in Latina, Italy, and Fishers, Indiana, along with better performance in the Engineering segment. Given the multi-year nature of these capacity investments, the report should provide useful signals on whether growth is converting into stronger profitability.
What the Numbers Are Expected to Show
Stevanato Group has not yet released its third-quarter fiscal 2026 results. For the same period last year, the company posted revenue of €303.2 million and diluted EPS of €0.13, or €0.14 on an adjusted basis. In the most recent quarter, revenue reached €302 million with adjusted diluted EPS of €0.14. Attention will center on whether the Biopharmaceutical and Diagnostic Solutions segment maintains high-single-digit growth, whether high-value solutions hold near their 45% revenue share, and whether overall margins continue to expand. Management’s full-year guidance of €1.26 billion to €1.28 billion in revenue and €0.60 to €0.62 in adjusted diluted EPS offers a useful benchmark for gauging progress. I also checked this using Tickeron’s AI Screener to compare the stock with peers in the healthcare space.
Market Sentiment and Potential Risks
Heading into the report, sentiment remains linked to the strength of the high-value product portfolio and the pace of margin recovery. The second-quarter results were generally viewed positively, with adjusted profitability improving even after one-time costs and a higher tax rate. Potential headwinds include foreign-exchange pressures, higher depreciation and utility expenses, and longer sales cycles in the Engineering segment. Investors will also listen for updates on GLP-1-related revenue, which accounted for roughly 22% to 23% of total revenue last quarter, and any commentary on the commercial progress of the Alina pen platform.
Forward Signals Worth Tracking
Beyond the headline results, several areas deserve close attention. The trajectory of high-value solutions, especially Nexa syringes and EZ-fill vials, will indicate whether biologics and GLP-1 demand can support further top-line growth. Capacity utilization at the Fishers and Latina plants is another focus; as volumes increase, operating leverage should improve, though near-term margins may still face pressure from depreciation and start-up costs. The Engineering segment’s optimization efforts remain a variable, with recent profitability gains tempered by caution around sales cycles. Progress on new orders, particularly in visual-inspection and assembly equipment, will help show whether this segment can achieve more consistent expansion. Any updates to full-year guidance, currency impacts, and the timeline for the Alina platform will round out the picture for assessing momentum into 2027.
AI Tools in My Research Process
One resource I turn to regularly when preparing for reports like this is Tickeron’s AI Screener. It helps me quickly filter stocks and ETFs by industry, technical patterns, fundamentals, and performance metrics, giving a clearer view of how names like STVN stack up against broader healthcare trends without spending hours on manual screening.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
STVN's Indicator enters downward trend
The Aroon Indicator for STVN entered a downward trend on October 27, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 172 similar instances where the Aroon Indicator formed such a pattern. In 154 of the 172 cases the stock moved lower. This puts the odds of a downward move at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 53 of 64 cases where STVN's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 83%.
STVN moved below its 50-day moving average on September 30, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for STVN crossed bearishly below the 50-day moving average on October 05, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where STVN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.
STVN broke above its upper Bollinger Band on October 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where STVN's RSI Indicator exited the oversold zone, 22 of 26 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.
The Momentum Indicator moved above the 0 level on October 22, 2026. You may want to consider a long position or call options on STVN as a result. In 80 of 97 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.
The Moving Average Convergence Divergence (MACD) for STVN just turned positive on October 23, 2026. Looking at past instances where STVN's MACD turned positive, the stock continued to rise in 52 of 56 cases over the following month. The odds of a continued upward trend are 90%.
Following a +0.36% 3-day Advance, the price is estimated to grow further. Considering data from situations where STVN advanced for three days, in 242 of 303 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 59 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 59 (best 1 - 100 worst), indicating fairly steady price growth. STVN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 74 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.479) is normal, around the industry mean (4.946). P/E Ratio (40.286) is within average values for comparable stocks, (38.797). Projected Growth (PEG Ratio) (1.538) is also within normal values, averaging (4.143). Dividend Yield (0.003) settles around the average of (0.005) among similar stocks. P/S Ratio (4.348) is also within normal values, averaging (56.876).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. STVN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry PharmaceuticalsOther
Advertisement